Plain-English translation of NCT04195347 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether , a new intravenous medication, can safely reduce the severity of pancreas inflammation (pancreatitis) that sometimes develops as a side effect in young cancer patients receiving asparaginase therapy. The study will enroll up to 42 young people with acute lymphoblastic leukemia or lymphoma who develop acute pancreatitis after asparaginase treatment. Researchers will give the medication over four days and track how well it works and what side effects occur.
Asparaginase is an important, life-saving chemotherapy drug for childhood leukemia and lymphoma, but it can cause severe pancreas inflammation in some patients. This trial exists to see whether this new treatment can reduce that risk and protect patients' health during cancer therapy.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an intravenous infusion (IV) for four days starting within 36 hours of your pancreas inflammation symptoms. The study uses a step-wise approach, starting with lower doses in early groups of patients and increasing doses if the treatment is well tolerated. After treatment ends, you would be followed by the research team for about four months with check-ins to monitor your recovery and watch for any side effects.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States